관상동맥 질환 치료제 시장 : 약제 유형별, 유통 채널별, 지역별

Coronary Artery Disease Therapeutics Market is estimated to be valued at USD 15.1 Bn in 2026 and is expected to reach USD 22.3 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.7% from 2026 to 2033.

The market is expected to witness steady growth due to the rising prevalence of coronary artery disease (CAD), increasing incidence of cardiovascular disorders, growing aging population, and continuous advancements in lipid-lowering and preventive cardiovascular therapies. The increasing burden of obesity, diabetes, hypertension, dyslipidemia, and sedentary lifestyles is further expanding the patient pool requiring long-term cardiovascular treatment.

Coronary artery disease therapeutics comprise a broad range of pharmaceutical treatments designed to prevent, manage, and reduce cardiovascular complications associated with coronary artery narrowing and plaque formation. These therapies include statins, beta blockers, ACE inhibitors, nitrates, calcium channel blockers, and other cardiovascular medications that help control cholesterol levels, regulate blood pressure, improve blood flow, and reduce the risk of myocardial infarction and other cardiovascular events. The growing emphasis on preventive cardiology and early intervention continues to strengthen demand for effective CAD therapeutics globally.

The market expansion is further supported by increasing investments in cardiovascular research, favorable reimbursement policies, growing awareness regarding heart health, and the introduction of innovative therapies such as PCSK9 inhibitors, RNA-based cholesterol-lowering drugs, and gene-editing approaches. Furthermore, the integration of digital health technologies, remote patient monitoring solutions, and AI-assisted cardiovascular care is creating favorable conditions for market growth.

Market Dynamics

The Coronary Artery Disease Therapeutics Market is influenced by a combination of epidemiological, technological, regulatory, and healthcare-access factors.

A major growth driver is the increasing prevalence of coronary artery disease and associated cardiovascular risk factors worldwide. Rising rates of obesity, diabetes, hypertension, smoking, and physical inactivity continue to contribute significantly to CAD incidence. As cardiovascular diseases remain the leading cause of mortality globally, healthcare systems are increasingly prioritizing preventive and long-term cardiovascular care, resulting in sustained demand for therapeutic interventions.

Another key growth driver is the increasing adoption of advanced lipid-lowering and cardioprotective therapies. The introduction of PCSK9 inhibitors, siRNA-based therapies such as inclisiran, and emerging gene-editing technologies targeting cholesterol metabolism pathways is improving treatment outcomes for high-risk patients. Growing clinical evidence supporting intensive cholesterol management and cardiovascular risk reduction is encouraging broader physician adoption of innovative therapies.

Technological advancements are also contributing significantly to market growth. The integration of artificial intelligence, telecardiology platforms, wearable cardiac monitoring devices, and digital patient-support programs is enhancing disease management, improving medication adherence, and facilitating early intervention. These innovations are helping healthcare providers deliver more personalized and efficient cardiovascular care.

However, the market faces challenges including the high cost of advanced cardiovascular therapies, limited accessibility in low- and middle-income countries, lengthy regulatory approval processes, and pricing pressures from healthcare payers. Despite these challenges, continued innovation in cardiovascular medicine, expanding healthcare infrastructure, and growing awareness of preventive care are expected to support long-term market expansion.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Coronary Artery Disease Therapeutics Market based on the following parameters - company highlights, service portfolio, key developments, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca, Gilead, Novartis, Pfizer, Bayer, Merck & Co., GlaxoSmithKline plc, Mylan N.V.
• Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
• The Coronary Artery Disease Therapeutics Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
• Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Coronary Artery Disease Therapeutics Market

Market Segmentation

• By Drug Type (Revenue, USD Bn, 2026-2033)
• Beta Blockers
• Statins
• ACE Inhibitors
• Nitrates
• Calcium Channel Blockers
• Others
• By Distribution Channel (Revenue, USD Bn, 2026-2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region (Revenue, USD Bn, 2026-2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
• AstraZeneca
• Gilead
• Novartis
• Pfizer
• Bayer
• Merck & Co.
• GlaxoSmithKline Plc
• Mylan N.V.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Disease Type Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Global Coronary Artery Disease Therapeutics Market, By Drug Type, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Beta Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Statins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• ACE Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Nitrates
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Calcium Channel Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Coronary Artery Disease Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Coronary Artery Disease Therapeutics Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • AstraZeneca
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Gilead
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Novartis
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Bayer
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Merck & Co.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

8. Section

• References
• Research Methodology
• About Us